TDMS Study 93029-04 Pathology Tables
NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03 Route: DOSED FEED Time: 07:04:42 Facility: National Center for Toxicological Research Chemical CAS #: 129-73-7 Lock Date: None Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03 Route: DOSED FEED Time: 07:04:42 ____________________________________________________________________________________________________________________________________ C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 48 48 48 48 Early Deaths Natural Death 7 2 2 5 Moribund 4 5 7 4 Survivors Terminal Sacrifice 37 41 39 39 Animals Examined Microscopically 47 48 47 47 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (44) (47) (44) (46) Intestine Large (46) (48) (47) (46) Intestine Small (44) (47) (47) (46) Ileum, Sarcoma, Metastatic, Ovary 1 (2%) Jejunum, Adenoma 1 (2%) Liver (47) (48) (47) (47) Hemangiosarcoma 1 (2%) 1 (2%) Hepatocellular Carcinoma 1 (2%) 2 (4%) Hepatocellular Adenoma 3 (6%) 6 (13%) 4 (9%) 8 (17%) Hepatocellular Adenoma, Two 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%) Pancreas (45) (48) (47) (45) Sarcoma, Metastatic, Skin 1 (2%) Sarcoma, Metastatic, Skeletal Muscle 1 (2%) Salivary Glands (47) (48) (47) (47) Stomach (46) (48) (47) (46) Forestomach, Mast Cell Tumor Malignant 1 (2%) Forestomach, Squamous Cell Carcinoma 1 (2%) Forestomach, Squamous Cell Papilloma 2 (4%) 1 (2%) 1 (2%) Glandular, Sarcoma, Metastatic, Skin 1 (2%) Glandular, Sarcoma, Metastatic, Skeletal Muscle 1 (2%) ____________________________________________________________________________________________________________________________________ Page 2 NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03 Route: DOSED FEED Time: 07:04:42 ____________________________________________________________________________________________________________________________________ C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (47) (48) (47) (47) Sarcoma, Metastatic, Skin 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Islets, Pancreatic (44) (48) (47) (45) Adenoma 1 (2%) Pituitary Gland (41) (45) (44) (46) Pars Distalis, Adenoma 3 (7%) 1 (2%) 2 (4%) Thyroid Gland (46) (48) (47) (47) Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (46) (48) (47) (44) Choriocarcinoma 1 (2%) Cystadenocarcinoma 1 (2%) Cystadenoma 1 (2%) Granulosa Cell Tumor Malignant 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma 1 (2%) Teratoma Benign 2 (4%) Uterus (46) (48) (47) (46) Hemangioma 1 (2%) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Leiomyoma 1 (2%) 1 (2%) Sarcoma Stromal 2 (4%) Vagina (45) (47) (47) (46) Mast Cell Tumor Malignant 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) ____________________________________________________________________________________________________________________________________ Page 3 NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03 Route: DOSED FEED Time: 07:04:42 ____________________________________________________________________________________________________________________________________ C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (46) (48) (47) (46) Hemangiosarcoma 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) Mast Cell Tumor Malignant 1 (2%) Lymph Node (47) (48) (47) (47) Lumbar, Histiocytic Sarcoma 1 (2%) Mandibular, Histiocytic Sarcoma 1 (2%) Mandibular, Mast Cell Tumor Malignant 1 (2%) Mesenteric, Histiocytic Sarcoma 1 (2%) Mesenteric, Sarcoma, Metastatic, Skin 2 (4%) Spleen (45) (48) (47) (45) Hemangiosarcoma 2 (4%) Thymus (43) (45) (45) (43) Histiocytic Sarcoma 1 (2%) Mast Cell Tumor Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (46) (48) (47) (45) Adenoacanthoma 2 (4%) 1 (2%) Carcinoma 1 (2%) 1 (2%) 1 (2%) 4 (9%) Carcinoma, Two 1 (2%) Skin (46) (48) (45) (45) Fibrous Histiocytoma 1 (2%) Hemangioma 1 (2%) Hemangiosarcoma 1 (2%) Mast Cell Tumor Benign 1 (2%) Mast Cell Tumor Malignant 1 (2%) Sarcoma 1 (2%) 2 (4%) Tail, Hemangioma 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (47) (48) (47) (46) Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03 Route: DOSED FEED Time: 07:04:42 ____________________________________________________________________________________________________________________________________ C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (47) (48) (47) (47) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (47) (48) (47) (47) Adenoacanthoma, Metastatic, Mammary Gland 2 (4%) Alveolar/Bronchiolar Adenoma 3 (6%) 1 (2%) 2 (4%) 1 (2%) Alveolar/Bronchiolar Carcinoma 2 (4%) Carcinoma, Metastatic, Mammary Gland 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Sarcoma, Metastatic, Skin 2 (4%) Sarcoma, Metastatic, Skeletal Muscle 1 (2%) Nose (47) (48) (47) (47) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (47) (48) (47) (47) Adenocarcinoma 1 (2%) 1 (2%) Adenoma 2 (4%) 2 (4%) 4 (9%) 4 (9%) Bilateral, Adenoma 1 (2%) Zymbal's Gland (47) (47) (46) (47) Mast Cell Tumor Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (47) (48) (47) (47) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Urinary Bladder (46) (48) (47) (44) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Page 5 NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03 Route: DOSED FEED Time: 07:04:42 ____________________________________________________________________________________________________________________________________ C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(47) *(48) *(47) *(47) Hemangioma 1 (2%) 1 (2%) Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%) Lymphoma Malignant 6 (13%) 5 (10%) 12 (26%) 6 (13%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 6 NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03 Route: DOSED FEED Time: 07:04:42 ____________________________________________________________________________________________________________________________________ C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 28 22 26 32 Total Primary Neoplasms 48 30 35 41 Total Animals with Benign Neoplasms 16 14 13 19 Total Benign Neoplasms 17 15 15 20 Total Animals with Malignant Neoplasms 16 11 18 17 Total Malignant Neoplasms 31 15 20 21 Total Animals with Metastatic Neoplasms 3 1 4 Total Metastatic Neoplasm 3 3 12 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 7 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------